Aripiprazole is an atypical antipsychotic acting as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors, used for schizophrenia, bipolar disorder and as an adjunct in major depression. Simson Pharma's Aripiprazole reference standard and impurities support the high-volume generic testing this widely prescribed antipsychotic demands.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Aripiprazole Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.